← Leaderboards
Daniel Meruelo
New York University School Of Medicine
$5,698,345
Attributed
$7,898,345
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$7,898,345 · 5
By mechanism
R44$4,400,000 · 2
R01$3,498,345 · 3
Top collaborators
- Jennifer June Sessions3 shared
- Scott Budd Winram2 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Sylvia Adams$1,535,260
- James L Salzer$22,072,768
- Tyler Dallas Bold$5,726,423
- Francesca M Gany$19,018,531
Others in their field
Top investigators on “Sindbis Virus”
- Beth C Levine · Columbia University Health Sciences$12,279,328
- Diane E Griffin · Johns Hopkins University$10,165,824
- Timothy O'Connor · Rockefeller University$7,019,416
- Margaret Kielian · Albert Einstein College Of Medicine$6,874,114
- Margaret R Macdonald · Rockefeller University$6,510,029
- David S Perlin · Hackensack University Medical Center$5,580,377
Research focus
Sindbis VirusApoptosisGene TherapyDisseminated Malignant NeoplasmCancer TherapyBaseCellsTransfection /Expression VectorVectorDoseTumorViral VectorScid MouseCommercializationGenerationsLeadAnimal ModelInvestigational New Drug ApplicationMalignant Neoplasm Of OvaryImmunotherapeutic AgentEpithelial Ovarian CancerChemotherapyImmune ResponseImmunotherapy
Grant awards (17)
A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer$866,737
R44 · FY2022 · CA
A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer$1,133,263
R44 · FY2021 · CA
A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer$400,000
R44 · FY2020 · CA
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy$1,004,186
R44 · FY2017 · CA
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy$995,814
R44 · FY2016 · CA
Sindbis Vectors For Advanced Pancreatic Cancer Therapy$286,653
R01 · FY2008 · CA · contact PI
Sindbis Vectors For Advanced Pancreatic Cancer Therapy$286,653
R01 · FY2007 · CA · contact PI
Sindbis Vectors For Advanced Pancreatic Cancer Therapy$295,214
R01 · FY2006 · CA · contact PI
Sindbis Vectors For Advanced Pancreatic Cancer Therapy$302,318
R01 · FY2005 · CA
Sindbis Vectors For Advanced Pancreatic Cancer Therapy$319,568
R01 · FY2004 · CA
Targetable Vectors for Gene Therapy$273,900
R01 · FY2004 · CA
Targetable Vectors for Gene Therapy$273,900
R01 · FY2003 · CA
GENETICS OF RESISTANCE TO LEUKEMIA$311,257
R01 · FY2002 · CA
Targetable Vectors for Gene Therapy$273,900
R01 · FY2002 · CA
GENETICS OF RESISTANCE TO LEUKEMIA$304,043
R01 · FY2001 · CA
Targetable Vectors for Gene Therapy$273,900
R01 · FY2001 · CA
GENETICS OF RESISTANCE TO LEUKEMIA$297,039
R01 · FY2000 · CA